Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Inclusion Criteria

• •Patients who meet all of the following criteria are eligible for the project:
• •Age ≥ 18 years
• •Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
• •Main project (Metatstatic NSCLC):
• •Confirmed non-small cell lung cancer (NSCLC)
• •Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only"
• •Stage IV, or stage IIIB/C (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy
• •Systemic therapy or best supportive care
• •Satellite Stage I/II/III (NSCLC):
• •Confirmed non-small cell lung cancer (NSCLC)
• •Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
• •Stage I, Stage II, stage IIIA, or stage IIIB/C (UICC8)
• •Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
• •Satellite SCLC
• •Confirmed Small cell lung cancer (SCLC)
• •Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
• •Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care